FAQ

Arterial Hypertension stem cell therapy — your questions answered (2026)

Medical review statusPending clinical sign-offLast evidence update: 2026-08-05Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

About stem cell therapy for Arterial Hypertension

Arterial hypertension is persistently elevated systemic blood pressure with multiple genetic, renal, endocrine, vascular, medicine-related and lifestyle contributors. Cell or exosome research may examine vascular or renal mechanisms, but it has not established a replacement for validated diagnosis, lifestyle measures and antihypertensive medicines.

The evidence for Arterial Hypertension

Blood pressure requires repeated valid measurement and assessment of cardiovascular risk and secondary causes. The NHLBI treatment overview describes heart-healthy lifestyle measures, monitoring and medicines. Experimental biomarker or endothelial findings do not show fewer strokes, heart attacks, kidney events or deaths, and must not justify stopping prescribed treatment.

Compare any research offer with the cost and benefit of accurate monitoring, cause-specific assessment and established medicines, not with a marketing claim about vascular rejuvenation. Itemise product, protocol tests, travel, follow-up and complication care and preserve continuous blood-pressure treatment.

Can stem cells lower blood pressure?

Cell therapy for Arterial Hypertension may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Will I stop medication?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How is it delivered?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Arterial Hypertension programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

Before deciding, verify the exact product, legal route, evidence, risks, alternatives and total cost. An online checklist is educational only and cannot determine candidacy.

← Back to Arterial Hypertension overview · Arterial Hypertension cost →

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information